Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: State of the art and future developments

Europace

Volumn 14, Issue 2, 2012, Pages 175-183

  Van Der Werf, Christian ^a   Zwinderman, Aeilko H ^b   Wilde, Arthur A M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Aborted cardiac arrest; Adrenergic antagonists; Calcium channel blockers; Catecholaminergic polymorphic ventricular tachycardia; Flecainide; Sudden cardiac death; Sympathectomy; Syncope; Therapy; Treatment

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; FLECAINIDE; NADOLOL; VERAPAMIL;

CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; DEFIBRILLATOR; DENERVATION; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; GENE MUTATION; HEART ARREST; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH; SYMPATHETIC DENERVATION; SYNCOPE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIAC RESYNCHRONIZATION THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; SURVIVAL ANALYSIS; SURVIVAL RATE; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME;

EID: 84856290184     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur277     Document Type: Review

References (71)

1. Coumel P, Fidelle J, Lucet V, Attuel P, Bouvrain Y. Catecholamine-induced severe ventricular arrhythmias with Adam-Stokes in children: report of four cases. Br Heart J 1978; 40: 28-37.
2. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995; 91: 1512-9.
3. Bai R, Napolitano C, Bloise R, Monteforte N, Priori SG. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. Circ Arrhythm Electrophysiol 2009; 2: 6-15.
4. Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, Hofman N, Bikker H, van Tintelen JP et al. The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. J Am Coll Cardiol 2009; 54: 2065-74.
5. 2+ release (SOICR). Proc Natl Acad Sci USA 2004; 101: 13062-7. (Pubitemid 39167583)
6. di Barletta MR, Viatchenko-Karpinski S, Nori A, Memmi M, Terentyev D, Turcato F et al. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation 2006; 114: 1012-9. (Pubitemid 44358877)
7. Lehnart SE, Wehrens XH, Laitinen PJ, Reiken SR, Deng SX, Cheng Z et al. Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak. Circulation 2004; 109: 3208-14.
8. 2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 2006; 116: 2510-20.
9. Cerrone M, Noujaim SF, Tolkacheva EG, Talkachou A, O'Connell R, Berenfeld O et al. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res 2007; 101: 1039-48. (Pubitemid 350084981)
10. Bhuiyan ZA, Hamdan MA, Shamsi ET, Postma AV, Mannens MM, Wilde AA. A novel early onset lethal form of catecholaminergic polymorphic ventricular tachycardia maps to chromosome 7p14-p22. J Cardiovasc Electrophysiol 2007; 18: 1060-6. (Pubitemid 47416570)
11. Tester DJ, Arya P, Will M, Haglund CM, Farley AL, Makielski JC et al. Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing. Heart Rhythm 2006; 3: 800-5. (Pubitemid 43960545)
12. Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001; 10: 189-94. (Pubitemid 32123976)
13. Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 2009; 119: 2426-34.
14. Postma AV, Denjoy I, Hoorntje TM, Lupoglazoff JM, Da CA, Sebillon P et al. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res 2002; 91: e21-6.
15. Lahat H, Eldar M, Levy-Nissenbaum E, Bahan T, Friedman E, Khoury A et al. Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation 2001; 103: 2822-7. (Pubitemid 32550071)
16. Haugaa KH, Leren IS, Berge KE, Bathen J, Loennechen JP, Anfinsen OG et al. High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening. Europace 2010; 12: 417-23.
17. Berg KJ. Multifocal ventricular extrasystoles with Adams-Stokes syndrome in children. Am Heart J 1960; 60: 965-70.
18. Horan M, Venables AW. Paroxysmal tachycardia with episodic unconsciousness. Arch Dis Child 1962; 37: 82-5.
19. Reid DS, Tynan M, Braidwood L, Fitzgerald GR. Bidirectional tachycardia in a child. A study using His bundle electrography. Br Heart J 1975; 37: 339-44.
20. Choi G, Kopplin LJ, Tester DJ, Will ML, Haglund CM, Ackerman MJ. Spectrum and frequency of cardiac channel defects in swimming-triggered arrhythmia syndromes. Circulation 2004; 110: 2119-24. (Pubitemid 39372488)
21. Swan H, Piippo K, Viitasalo M, Heikkila P, Paavonen T, Kainulainen K et al. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol 1999; 34: 2035-42. (Pubitemid 30002662)
22. Katz G, Arad M, Eldar M. Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond. Curr Probl Cardiol 2009; 34: 9-43.
23. Bauce B, Rampazzo A, Basso C, Bagattin A, Daliento L, Tiso N et al. Screening for ryanodine receptor type 2 mutations in families with effort-induced polymorphic ventricular arrhythmias and sudden death: early diagnosis of asymptomatic carriers. J Am Coll Cardiol 2002; 40: 341-9. (Pubitemid 34756298)
24. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106: 69-74. (Pubitemid 34747444)
25. Sumitomo N, Harada K, Nagashima M, Yasuda T, Nakamura Y, Aragaki Y et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart 2003; 89: 66-70. (Pubitemid 36044293)
26. Postma AV, Denjoy I, Kamblock J, Alders M, Lupoglazoff JM, Vaksmann G et al. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet 2005; 42: 863-70. (Pubitemid 41598196)
27. Celiker A, Erdogan I, Karagoz T, Ozer S. Clinical experiences of patients with catecholaminergic polymorphic ventricular tachycardia. Cardiol Young 2009; 19: 45-52.
28. Sy RW, Gollob MH, Klein GJ, Yee R, Skanes AC, Gula LJ et al. Arrhythmia characterizationc and longl-term outcomeso in catecholaminergic polymorphic ventricular tachycardiacpvt. Heart Rhythm 2011; 8: 864-71.
29. Song MK, Baek JS, Kwon BS, Kim GB, Bae EJ, Noh CI et al. Clinical spectrum and prognostic factors of pediatric ventricular tachycardia. Circ J 2010; 74: 1951-8.
30. Allouis M, Probst V, Jaafar P, Schott JJ, Le MH. Unusual clinical presentation in a family with catecholaminergic polymorphic ventricular tachycardia due to a G14876A ryanodine receptor gene mutation. Am J Cardiol 2005; 95: 700-2. (Pubitemid 40255277)
31. Triggle DJ. L-type calcium channels. Curr Pharm Des 2006; 12: 443-57.
32. Swan H, Laitinen P, Kontula K, Toivonen L. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophysiol 2005; 16: 162-6. (Pubitemid 40326272)
33. Rosso R, Kalman JM, Rogowski O, Diamant S, Birger A, Biner S et al. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2007; 4: 1149-54. (Pubitemid 47324118)
34. Rosso R, Kalman J, Rogowsky O, Diamant S, Birger A, Biner S et al. Long-term effectiveness of beta blocker and calcium blocker combination therapy in patients with CPVT. Heart Rhythm 2010; 7: S423.
35. Katz G, Khoury A, Kurtzwald E, Hochhauser E, Porat E, Shainberg A et al. Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice. Heart Rhythm 2010; 7: 1676-82.
36. Alcalai R, Wakimoto H, Arad M, Planer D, Konno T, Wang L et al. Prevention of Ventricular Arrhythmia and Calcium Dysregulation in a Catecholaminergic Polymorphic Ventricular Tachycardia Mouse Model Carrying Calsequestrin-2 Mutation. J Cardiovasc Electrophysiol 2010; 22: 316-24.
37. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009; 15: 380-3.
38. van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 2011; 57: 2244-54.
39. 2+ spark mass. J Mol Cell Cardiol 2010; 48: 293-301.
40. Biernacka EK, Hofmann P. Efficacy of flecainide in a patient with catecholaminergic polymorphic ventricular tachycardia. Europace 2011; 13: 129-30.
41. Pott C, Dechering DG, Reinke F, Muszynski A, Zellerhoff S, Bittner A et al. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature. Europace 2011; 13: 897-901.
42. Sumitomo N, Sakurada H, Taniguchi K, Matsumura M, Abe O, Miyashita M et al. Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia. Circ J 2007; 71: 1606-9. (Pubitemid 47529664)
43. van der Werf C, Wilde AA. Catecholaminergic polymorphic ventricular tachycardia: important messages from case reports. Europace 2011; 13: 11-3.
44. Wilde AA, Bhuiyan ZA, Crotti L, Facchini M, De Ferrari GM, Paul T et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med 2008; 358: 2024-9. (Pubitemid 351656456)
45. Jonnesco T. Traitement chirurgical de l'angine de poitrine par la résection du sympathique cervico-thoracique. Presse Med 1921; 20: 221-30.
46. Leriche R, Fontaine R. The surgical treatment of angina pectoris: what it is and what it should be. Am Heart J 1928; 3: 649-71.
47. Schwartz PJ, Malliani A. Electrical alternation of the T-wave: clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long Q-T syndrome. Am Heart J 1975; 89: 45-50.
48. Schwartz PJ, Snebold NG, Brown AM. Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold. Am J Cardiol 1976; 37: 1034-40.
49. Schwartz P, Motolese M, Pollavini G, the Italian Sudden Death Prevention Group. Prevention of sudden cardiac death after a first myocardial infarction by pharmacologic or surgical antiadrenergic interventions. J Cardiovasc Electrophysiol 1992; 3: 2-16.
50. Scott PA, Sandilands AJ, Morris GE, Morgan JM. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with bilateral thoracoscopic sympathectomy. Heart Rhythm 2008; 5: 1461-3.
51. Atallah J, Fynn-Thompson F, Cecchin F, DiBardino DJ, Walsh EP, Berul CI. Video-assisted thoracoscopic cardiac denervation: a potential novel therapeutic option for children with intractable ventricular arrhythmias. Ann Thorac Surg 2008; 86: 1620-5.
52. Collura CA, Johnson JN, Moir C, Ackerman MJ. Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. Heart Rhythm 2009; 6: 752-9.
53. Gopinathannair R, Olshansky B, Iannettoni M, Mazur A. Delayed maximal response to left cardiac sympathectomy for catecholaminergic polymorphic ventricular tachycardia. Europace 2010; 12: 1035-9.
54. Chen SY, Cucchiaro G, Bushman G. The Role of Thoracic Epidural Blockade in Predicting Responsiveness to Left Sympathetic Denervation in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. J Cardiothorac Vasc Anesth 2010. Epub ahead of print.
55. Odero A, Bozzani A, De Ferrari GM, Schwartz PJ. Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: the surgical supraclavicular approach to cervicothoracic sympathectomy. Heart Rhythm 2010; 7: 1161-5.
56. Makanjee B, Gollob MH, Klein GJ, Krahn AD. Ten-year follow-up of cardiac sympathectomy in a young woman with catecholaminergic polymorphic ventricular tachycardia and an implantable cardioverter defibrillator. J Cardiovasc Electrophysiol 2009; 20: 1167-9.
57. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e385-484.
58. Garratt CJ, Elliott P, Behr E, Camm AJ, Cowan C, Cruickshank S et al. Heart Rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromes. Europace 2010; 12: 1156-75.
59. Mohamed U, Gollob MH, Gow RM, Krahn AD. Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. Heart Rhythm 2006; 3: 1486-9. (Pubitemid 44849373)
60. Palanca V, Quesada A, Trigo A, Jimenez J. Arrhythmic storm induced by AICD discharge in a patient with catecholaminergic polymorphic ventricular tachycardia. Rev Esp Cardiol 2006; 59: 1079-80. (Pubitemid 44823392)
61. Pizzale S, Gollob MH, Gow R, Birnie DH. Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 2008; 19: 1319-21.
62. Moray A, Kirk EP, Grant P, Camphausen C. Prophylactic left thoracic sympathectomy to prevent electrical storms in CPVT patients needing ICD placement. Heart Lung Circ 2011, April 6. Epub ahead of print.
63. Sherrid MV, Daubert JP. Risks and challenges of implantable cardioverterdefibrillators in young adults. Prog Cardiovasc Dis 2008; 51: 237-63.
64. 2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 2011; 4: 128-35.
65. Kobayashi S, Yano M, Uchinoumi H, Suetomi T, Susa T, Ono M et al. Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S/+) knock-in mouse model. Circ J 2010; 74: 2579-84.
66. 2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest 2008; 118: 2230-45. (Pubitemid 351872341)
67. Wehrens XH, Lehnart SE, Reiken SR, Deng SX, Vest JA, Cervantes D et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 2004; 304: 292-6. (Pubitemid 38452182)
68. Liu N, Ruan Y, Denegri M, Bachetti T, Li Y, Colombi B et al. Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C±) mice with catecholaminergic polymorphic ventricular tachycardia. J Mol Cell Cardiol 2011; 50: 214-22.
69. Chen S, Duan Q, Tang K, Zhao D, Xu Y. Serotonin and catecholaminergic polymorphic ventricular tachycardia: a possible therapeutic role for SSRIs? Cardiovasc J Afr 2010; 21: 225-8.
70. Sumitomo N, Nakamura T, Fukuhara J, Nakai T, Watanabe I, Mugishima H et al. Clinical effectiveness of pulmonary vein isolation for arrhythmic events in a patient with catecholaminergic polymorphic ventricular tachycardia. Heart Vessels 2010; 25: 448-52.
71. Sumitomo N, Sakurada H, Mugishima H, Hiraoka M. Adenosine triphosphate terminates bidirectional ventricular tachycardia in a patient with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2008; 5: 496-7.